Review Article|Articles in Press, 103673

Plasmapheresis in ABO incompatible kidney transplant

Published:February 24, 2023DOI:


      In patients with an end-stage renal disease, dialysis a or kidney transplant are required to prolong live. For survival of the transplanted kidney, besides the HLA-system, the ABO blood type of donor and patient is also of importance. When the donor organ is derived from a living donor, time can be available prior to the transplant to reduce blood type AB antibodies in case of ABO major incompatibility between organ donor and recipient by double filtration apheresis.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Reid M.E.
        • Lomas-Francis C.
        • Olsson M.L.
        The blood group antigen facts book. 3rd edition.,. Elsevier Science Publishing Co Inc, Academic Press Inc,, 2012
        • Shimmura H.
        • Tanabe K.
        • Ishikawa N.
        • Tokumoto T.
        • Takahashi K.
        • Toma H.
        Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation.
        Transplantation. 2000; 15: 1331-1335
        • Genberg H.
        • Kumlien G.
        • Wennberg L.
        • Tydén G.
        Isoagglutinin adsorption in ABO-incompatible transplantation.
        Transfus Apher Sci. 2010; 43: 231-235
        • Dallaval Galvão de França N.
        • Caamaño Cristovão Poli M.
        • Guilhem de Almeida Ramos P.
        • Strang da Rocha Borsoi C.
        • Colella R.
        Titers of ABO antibodies in group O blood donors.
        Rev Bras Hematol Hemoter. 2011; 33: 259-262
        • Bazigou F.
        • Lempesopoulos K.
        • Kavallierou L.
        • Cheropoulou A.
        • Mouratidou M.
        • Baliaga S.
        • et al.
        Evaluation of anti-A and anti-B alloisogglutinin titer in group O plateletpheresis donors.
        Hematol Transfus Int J. 2015; 1: 76-81
        • Youk H.J.
        • Ryu H.Y.
        • Seo S.W.
        • Kim J.S.
        • Chung Y.
        • Kim H.
        • et al.
        A new trial to measure ABO antibodies using complement-dependent cytotoxicity.
        Medicina. 2022; 58: 830
        • Balint B.
        • Pavlovic M.
        • Todorovic M.
        • Jevtic M.
        • Ristanovic E.
        • Ignjatovic L.
        The use of original ex vivo immunoadsorption and ‘‘multi-manner” apheresis in ABO/H-mismatched kidney transplants—A phase II clinical study.
        Transfus Apher Sci. 2010; 43: 141-148
        • Tobian A.A.R.
        • Shirey R.S.
        • Montgomery R.A.
        • Caia W.
        • Haas M.
        • Ness P.M.
        • et al.
        ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation.
        Am J Transpl. 2010; 10: 1247-1253